The use of CPAP alone does not appear to improve hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease and obstructive sleep apnea.
TERN-201 is a highly-selective semicarbazide-sensitive amino oxidase inhibitor.
The NIS4 biomarker panel may provide a means for clinicians to avoid unnecessary liver biopsies in patients at low risk for NASH.
A team of investigators studied the relationship between changes in liver histology and changes in body mass index, dyslipidemia, and measures of glucose homeostasis in children.
A systematic review and meta-analysis of observational studies was conducted to assess the prevalence of nonalcoholic fatty liver disease in the general population.
As the role of the gut microbiome in nonalcoholic fatty liver disease is explored, research has turned to fecal microbiota transplantation as a potential treatment option.
Low thyroid function is associated with nonalcoholic fatty liver disease and predicted all-cause and cardiovascular mortality in this population.
Women with non-alcoholic fatty liver disease have increased risks for maternal and neonatal complications.
First responders to the World Trade Center attacks appear to have a much higher prevalence of hepatic steatosis than the general population.
The FDA has granted Fast Track designation to intravenous choline chloride (Protara Therapeutics), an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
Women have a lower overall risk of acquiring nonalcoholic fatty liver disease (NAFLD) than men do, but a higher risk of advanced fibrosis if NAFLD status is confirmed.
The lack of standardized diet and exercise recommendations across NAFLD/NASH clinical trials has posed a significant challenge in understanding their impact.
The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.
The clinical burden associated with nonalcoholic fatty liver disease is high.
Experts proposed new guidelines on the diagnosis of metabolic-associated fatty liver disease (MAFLD), formerly non-alcohol fatty liver disease (NAFLD).
Increased blood glucose levels, even within the nondiabetic range, are associated with increased risk for nonalcoholic fatty liver disease.
Noninvasive scoring systems have modest predictive ability to identify the future development of severe liver disease in patients in the general population.
Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S. patients with type 2 diabetes mellitus.
In this prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and with lower risk for progression to advanced fibrosis.
Findings of the analysis also revealed that some evidence indicates that liraglutide improves liver fat, liver function, and HbA1c, and may aid in NASH resolution and weight reduction.